Urogen Pharma

URGN Healthcare Biotechnology

Urogen Pharma’s revenue for fiscal 2025 (year ended December 2025) was $109.8 million, up 21.4% from fiscal 2024. In the quarter to June 2026, revenue grew 199.2%, EPS grew 73.3%, free cash flow grew 17.3% and total debt rose 56.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

34.56 2.05 −5.60%
Market cap
$1.8B
P/E
0.0×
Fwd P/E
−30.0×
Dividend yield
—
F-score
2/9
Altman Z
−5.16
Beneish M
−1.42
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
— — 2 4 3 3 4 6 5 2
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
— 30.27 27.15 16.01 2.69 (5.54) (5.94) (4.09) (2.85) (5.16)
P/S ratio
0.00 0.00 601.39 1,030.15 33.21 4.42 3.06 5.30 5.05 10.26
P/FCF ratio
48.35 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
4.30 12.27 3.77 5.45 (7.50) (12.78) (13.13) (10.10) (6.22) (15.59)
Beneish M-Score
— — — — — (1.27) (4.04) (2.80) (2.82) (1.42)
P/Operating CF
(11.75) (63.01) (65.96) (26.35) (18.48) (10.59) (9.06) (33.75) (33.53) (29.40)
P/B ratio
1.98 5.48 7.53 3.80 4.07 25.26 0.00 0.00 0.00 0.00
Price to Tangible BV
1.98 5.48 7.53 3.80 4.07 25.26 0.00 0.00 0.00 0.00
EV/Sales
0.00 0.00 511.34 812.12 24.60 2.55 3.01 4.83 3.77 10.30
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Operating CF
9.94 (31.59) (15.45) (7.60) (2.75) (1.44) (2.21) (5.23) (3.52) (6.96)
EV/FCF
21.38 (30.72) (15.22) (7.57) (2.71) (1.43) (2.21) (5.22) (3.51) (6.95)
Quick Ratio
6.87 10.40 7.54 7.58 5.15 4.56 4.75 4.91 5.62 3.34
Current Ratio
7.03 10.59 7.59 7.63 5.39 5.11 5.39 5.42 6.01 4.01
Net Debt/EBITDA
(21.22) 3.71 1.32 1.32 0.81 0.99 0.04 0.60 1.17 0.00
Debt/Assets
0.00% 0.00% 0.00% 1.29% 1.23% 0.33% 71.92% 55.27% 42.61% 60.97%
Debt/Equity
0.00 0.00 0.00 0.01 0.02 0.05 (1.09) (1.51) (13.83) (1.16)
Asset Turnover
0.83 0.17 0.01 0.00 0.07 0.40 0.50 0.53 0.39 0.45
Operating CF/Net income
(2.16) 0.48 0.49 0.68 0.82 0.77 0.80 0.75 0.76 1.06
Capex/Depreciation
(3.26) (1.31) (1.34) 1.18 (1.42) (0.58) (0.60) 0.84 0.12 0.18
Interest Coverage
0.29 (643.55) (41.23) (23.72) (63.82) (252.85) (9.37) (4.45) (7.73) (8.14)
ROE
(11.92%) (47.16%) (95.40%) (77.77%) (92.88%) (211.55%) 271.24% 132.29% 342.83% 268.63%
ROA
(9.15%) (40.57%) (84.48%) (68.73%) (79.22%) (91.68%) (85.98%) (65.14%) (54.68%) (63.14%)
ROIC
0.00% 0.00% 0.00% (193.80%) 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(9.88%) (29.31%) (84.32%) (80.80%) (133.52%) (117.92%) (103.29%) (73.74%) (54.96%) (109.45%)
Average Days of Receivables
1.73 0.00 0.00 0.00 218.00 89.02 72.05 68.15 81.97 109.98
Research and Development Expense of Revenue
58.68% 229.19% 3,274.29% 273,872.22% 400.97% 99.17% 82.21% 55.15% 63.21% 61.12%
Selling, General and Administrative Expense of Revenue
36.61% 108.00% 3,508.07% 334,438.89% 764.63% 182.21% 128.72% 112.77% 134.02% 141.27%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
11.22% 77.22% 2,716.49% 166,483.33% 237.52% 48.11% 16.44% 11.30% 14.50% 10.89%
Graham Net Nets
0.59 0.18 0.13 0.18 0.23 0.01 (0.49) (0.17) (0.04) (0.11)
Graham Number
0.00 0.00 0.00 0.00 0.00 0.00 20.53 13.78 3.86 12.56
Earnings Yield
(43.78%) (7.61%) (11.05%) (15.31%) (32.85%) (52.16%) (55.32%) (24.52%) (30.33%) (13.66%)
Free Cash Flow Yield
2.07% (2.62%) (5.59%) (10.41%) (27.29%) (40.30%) (44.56%) (17.46%) (21.27%) (14.44%)
Revenue per Share
7.60 0.84 0.07 0.00 0.54 2.15 2.82 2.87 2.11 2.28
Operating CF per Share
1.82 (0.98) (2.37) (3.46) (4.86) (3.80) (3.84) (2.65) (2.26) (3.38)
Capex per Share
(0.30) (0.03) (0.04) (0.02) (0.06) (0.03) (0.01) (0.01) (0.01) (0.01)
Free Cash Flow per Share
1.52 (1.01) (2.41) (3.48) (4.92) (3.83) (3.85) (2.66) (2.26) (3.38)
Cash per Share
9.31 7.53 6.45 7.19 4.74 4.04 4.42 4.78 5.55 2.53
Shareholders Equity per Share
7.07 7.05 5.72 8.78 4.42 0.38 (3.92) (2.26) (0.21) (2.19)
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
7.07 7.05 5.72 8.78 4.42 0.38 (3.92) (2.26) (0.21) (2.19)
Free Cash Flow
3.49 (9.84) (37.89) (71.34) (107.10) (85.64) (87.81) (76.57) (97.06) (162.73)
Working Capital
18.90 67.44 88.78 129.15 94.18 92.01 104.99 137.97 230.19 139.61
Capital Expenditures
(0.69) (0.27) (0.56) (0.32) (1.21) (0.75) (0.25) (0.19) (0.29) (0.29)
Net Current Asset Value
15.29 67.44 88.78 126.55 89.97 3.06 (96.07) (74.34) (18.38) (119.90)
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capex to Sales
0.04 0.03 0.50 18.06 0.10 0.02 0.00 0.00 0.00 0.00
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.29 0.26 0.44 (0.28) 0.42 0.66 0.33 (0.34) (3.91) (2.46)
Cash ROIC
9.25% (6.94%) (19.77%) (21.59%) (53.26%) (86.36%) (80.60%) (44.74%) (27.68%) (117.46%)
Accounts Receivable Turnover
4.92 0.00 0.00 0.00 3.31 5.12 5.27 5.88 5.06 4.11
Accounts Payable Turnover
0.02 0.19 0.28 0.00 0.10 0.47 0.63 0.65 0.40 0.45
Inventory Turnover
0.13 2.85 5.71 — 0.89 1.52 1.67 1.87 1.19 0.97
Average Days of Payables
24,507.14 2,697.96 1,728.84 0.00 3,625.76 856.55 590.51 644.84 1,127.39 812.78
Days of Inventory on Hand
1,368.75 192.23 63.97 — 710.47 342.00 206.25 221.20 379.22 482.80
Average Receivables
3.57 — — — 3.57 9.38 12.21 14.07 17.87 26.69
Average Payables
1.80 3.16 6.49 9.86 10.60 11.06 12.24 14.46 21.98 27.57
Average Inventory
0.21 0.21 0.32 — 1.14 3.40 4.58 5.00 7.45 12.85
Average Assets
21.22 49.30 89.55 152.97 162.20 120.88 127.68 156.97 232.01 243.08
Average Common Equity
16.29 42.40 79.30 135.20 138.33 52.38 (40.47) (77.29) (37.01) (57.14)

Fold the line items

Columns are period end dates